Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Christopher P. Vellano
Niraparib Activates Interferon Signaling and Potentiates Anti-Pd-1 Antibody Efficacy in Tumor Models
Scientific Reports
Multidisciplinary
Related publications
PD-L1 Checkpoint Blockade Delivered by Retroviral Replicating Vector Confers Anti-Tumor Efficacy in Murine Tumor Models
Oncotarget
Oncology
Prognostic Significance of Pd-L1 and Phosphorylated Erk Expression in T-Cell Lymphoma: Pd-1/Pd-L1 Axis Activates Intracellular Erk Signaling in Tumor Cells
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Robust Antitumor Effects of Combined Anti-Cd4-Depleting Antibody and Anti-Pd-1/Pd-L1 Immune Checkpoint Antibody Treatment in Mice
Cancer immunology research
Cancer Research
Immunology
Poor Outcome With Anti-Programmed Death-Ligand 1 (PD-L1) Antibody Due to Poor Pharmacokinetic Properties in PD-1/PD-L1 Blockade-Sensitive Mouse Models
Journal for ImmunoTherapy of Cancer
Oncology
Molecular Medicine
Pharmacology
Cancer Research
Allergy
Immunology
Safety and Tumor Responses With Lambrolizumab (Anti–PD-1) in Melanoma
New England Journal of Medicine
Medicine
Anti-Tumor Efficacy and Biomarker Evaluation of Agonistic Anti-Ox40 Antibodies in Preclinical Models
Journal for ImmunoTherapy of Cancer
Oncology
Molecular Medicine
Pharmacology
Cancer Research
Allergy
Immunology
Rationale of Combination of Anti-Pd-1/Pd-L1 Antibody Therapy and Radiotherapy for Cancer Treatment
International Journal of Clinical Oncology
Medicine
Surgery
Oncology
Hematology
Comment on ‘Efficacy and Toxicity of Treatment With the Anti-Ctla-4 Antibody Ipilimumab in Patients With Metastatic Melanoma After Prior Anti-Pd-1 Therapy’
British Journal of Cancer
Cancer Research
Oncology
Myeloid Maturation Potentiates STAT3-mediated Atypical IFN-γ Signaling and Upregulation of PD-1 Ligands in AML and MDS
Scientific Reports
Multidisciplinary
